patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus potential COVID-19 treatments - for COVID-19 (hospitalized or not)
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 1.35 [0.63, 2.89]< 1 0% 1 study (-/1) 22.2 % NA not evaluable crucial - death or transfer to ICU 1.45 [1.33, 1.59]< 1 0% 2 studies (-/2) 0.0 % NA not evaluable crucial - deaths 0.93 [0.72, 1.19]< 1 86% 16 studies (1/15) 71.7 % NA low crucial - deaths (time to event analysis only) 0.58 [0.11, 3.12]< 1 86% 2 studies (-/2) 73.5 % NA not evaluable crucial - hospitalization or death 0.39 [0.26, 0.59]< 1 0% 1 study (-/1) 100.0 % NA not evaluable crucial - clinical improvement 1.32 [0.87, 2.00]> 1 0% 2 studies (2/-) 90.5 % some concern not evaluable moderate important - clinical improvement (28-day) 1.08 [0.54, 2.15]> 1 0% 1 study (1/-) 58.5 % NA not evaluable important - clinical improvement (7-day) 1.48 [0.88, 2.48]> 1 0% 1 study (1/-) 93.0 % NA not evaluable important - death or ventilation 1.63 [1.04, 2.55]< 1 0% 1 study (-/1) 1.7 % NA not evaluable important - hospitalization 0.82 [0.42, 1.59]< 1 94% 4 studies (-/4) 72.4 % NA not evaluable important - mechanical ventilation 1.01 [0.70, 1.45]< 1 0% 5 studies (1/4) 48.6 % NA not evaluable important - mechanical ventilation (time to event analysis only) 1.60 [0.51, 5.06]< 1 0% 1 study (-/1) 21.2 % NA not evaluable important - radiologic improvement (14-day) 3.16 [0.62, 16.10]> 1 0% 1 study (1/-) 91.6 % NA not evaluable important - viral clearance by day 7 2.62 [1.06, 6.46]> 1 0% 1 study (1/-) 98.2 % NA not evaluable important - ICU admission 1.13 [0.65, 1.99]< 1 0% 2 studies (-/2) 32.9 % NA not evaluable non important - severe COVID-19 occurrence 0.73 [0.34, 1.56]< 1 0% 1 study (-/1) 79.2 % NA not evaluable non important - 00 serious adverse events 1.44 [0.02, 87.17]< 1 0% 1 study (1/-) 43.2 % NA not evaluable important -
LoD: level of statistical demonstration:
